Methora 5 Tablet contains Methotrexate 5mg, a folate antagonist used primarily in the treatment of various neoplastic diseases, autoimmune disorders, and ectopic pregnancies. Methotrexate acts by inhibiting dihydrofolate reductase, an enzyme involved in the tetrahydrofolate synthesis pathway, thereby interfering with DNA synthesis, repair, and cellular replication, particularly in rapidly dividing cells. It is commonly prescribed for conditions such as rheumatoid arthritis, psoriasis, certain types of leukemia, and lymphomas. Methora 5 is administered orally, with dosage and treatment duration tailored to the specific condition and patient response. Due to its immunosuppressive and antiproliferative effects, regular monitoring of blood counts, liver and renal function is essential to minimize potential adverse effects, including hepatotoxicity, myelosuppression, and pulmonary toxicity. Patients should be advised to avoid alcohol consumption and to report any signs of infection, unexplained bruising, or bleeding promptly. Methora 5 is contraindicated in pregnancy and lactation due to its teratogenic potential. Careful assessment of patient history and concomitant medications is necessary to prevent drug interactions. Methora 5 Tablet should be used under strict medical supervision to ensure safe and effective therapy.